BeOne Medicines Ltd

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 6442.96, 7338.71, 8296.37, 9034.94, 10012.74 ], "ebit_estimate": [ 893.74, 1235.43, 1829.65, 2113.29, 2666.24 ], "ebitda_estimate": [ 1043.07, 1487.48, 2225.32, 3104.87, null ], "net_income_estimate": [ 728.16, 1099.46, 1582.02, 1788.05, 2273.65 ], "per_share_eps_estimate": [ 6.53, 9.16, 13.35, 14.93, 18.72 ], "eps_nri_estimate": [ 6.49, 9.82, 13.82, 14.93, 18.72 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 36.34, 46, 62.02, 93.43, null ], "pretax_income_estimate": [ 893.63, 1328.73, 1909.69, 2167.62, 2846.21 ], "operating_cash_flow_per_share_estimate": [ 7.63, 10.67, 12.99, 23.66, null ], "roa_estimate": [ 10.3, 15.27, 15.35, 15.37, null ], "roe_estimate": [ 16.04, 20.87, 23.43, 26.38, null ], "gross_margin_estimate": [ 87.33, 87.68, 88.02, 88.76, null ], "operating_cash_flow_estimate": [ 883.15, 1235.14, 1503.33, 2739.26, null ], "pettm_estimate": [ 45.76, 32.61, 22.38, 20.01, 15.96 ], "long_term_growth_rate_mean": 73.72, "long_term_revenue_growth_rate_mean": "15.59", "future_per_share_eps_estimate_growth": 71.29, "future_eps_nri_estimate_growth": 73.72, "future_revenue_estimate_growth": 15.59, "future_ebit_estimate_growth": 57.82, "future_ebitda_estimate_growth": 55.17, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 74.1, "future_pretax_income_estimate_growth": 64.36, "future_book_value_per_share_estimate_growth": 19.25, "future_roa_estimate_growth": 54.93, "future_roe_estimate_growth": 45.13, "future_gross_margin_estimate_growth": 0.28, "future_operating_cash_flow_per_share_estimate_growth": 12.06 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 1589.76, 1657.06, 1705.62, 1684.49, 1800.96, 1842.42, 1940.67, 1607.54 ], "ebit_estimate": [ 223.11, 230.95, 190.52, 305.88, 327.42, 334.28, 341.19, 283.95 ], "ebitda_estimate": [ 265.8, 284.79, 221.94, 346.71, 365.23, 371.4, 402.27, 346.71 ], "net_income_estimate": [ 162.75, 185.63, 153.63, 259.01, 275.17, 283.63, 291.2, 236.74 ], "per_share_eps_estimate": [ 1.52, 1.73, 1.39, 2.15, 2.21, 2.41, 3.45, null ], "eps_nri_estimate": [ 1.52, 1.75, 1.43, 2.25, 2.32, 2.53, 3.38, null ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 1.54, 1.58, null, null, null, null, null, 4.45 ], "pretax_income_estimate": [ 220.02, 225.23, 194.79, 309.3, 331.91, 339.83, 347.84, 291.7 ], "operating_cash_flow_per_share_estimate": [ 1.07, 2.61, 1.09, null, null, null, null, 0.28 ], "roa_estimate": [ null, null, 6.4, null, null, null, null, null ], "roe_estimate": [ 28.47, 26.27, 20.7, null, null, null, null, null ], "gross_margin_estimate": [ 87.36, 87.58, 87.23, null, null, null, null, null ], "operating_cash_flow_estimate": [ 123.88, 302.16, 126.19, null, null, null, null, 32.53 ], "pettm_estimate": [ 44.04, 39.97, 36.61, 29.24, null, null, null, null ], "long_term_growth_rate_mean": 73.72, "long_term_revenue_growth_rate_mean": "15.59", "future_per_share_eps_estimate_growth": 71.29, "future_eps_nri_estimate_growth": 73.72, "future_revenue_estimate_growth": 15.59, "future_ebit_estimate_growth": 57.82, "future_ebitda_estimate_growth": 55.17, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 74.1, "future_pretax_income_estimate_growth": 64.36, "future_book_value_per_share_estimate_growth": 19.25, "future_roa_estimate_growth": 54.93, "future_roe_estimate_growth": 45.13, "future_gross_margin_estimate_growth": 0.28, "future_operating_cash_flow_per_share_estimate_growth": 12.06 }